Literature DB >> 25281837

Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling.

Pilar Ortiz-Vilchis1, Katrina Go Yamazaki2, Ivan Rubio-Gayosso1, Israel Ramirez-Sanchez1, Claudia Calzada1, Diego Romero-Perez3, Alicia Ortiz4, Eduardo Meaney1, Pam Taub2, Francisco Villarreal2, Guillermo Ceballos5.   

Abstract

(-)-Epicatechin (EPI) is cardioprotective in the setting of ischemia/reperfusion (IR) injury and doxycycline (DOX) is known to preserve cardiac structure/function after myocardial infarction (MI). The main objective of this study was to examine the effects of EPI and DOX co-administration on MI size after IR injury and to determine if cardioprotection may involve the mitigation of mitochondrial swelling. For this purpose, a rat model of IR was used. Animals were subjected to a temporary 45 min occlusion of the left anterior descending coronary artery. Treatment consisted of a single or double dose of EPI (10 mg/kg) combined with DOX (5 mg/kg). The first dose was given 15 min prior to reperfusion and the second 12 h post-MI. The effects of EPI +/- DOX on mitochondrial swelling (i.e. mPTP opening) were determined using isolated mitochondria exposed to calcium overload and data examined using isobolographic analysis. To ascertain for the specificity of EPI effects on mitochondrial swelling other flavonoids were also evaluated. Single dose treatment reduced MI size by ~46% at 48 h and 44% at three weeks. Double dosing evidenced a synergistic, 82% reduction at 3 weeks. EPI plus DOX also inhibited mitochondrial swelling in a synergic manner thus, possibly accounting for the cardioprotective effects whereas limited efficacy was observed with the other flavonoids. Given the apparent lack of toxicity in humans, the combination of EPI and DOX may have clinical potential for the treatment of myocardial IR injury.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Doxycycline; Epicatechin; Ischemia-reperfusion; Mitochondrial swelling

Mesh:

Substances:

Year:  2014        PMID: 25281837      PMCID: PMC5109834          DOI: 10.1016/j.ejphar.2014.09.042

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

Review 1.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

2.  Vascular action of cocoa flavanols in humans: the roots of the story.

Authors:  Norman K Hollenberg
Journal:  J Cardiovasc Pharmacol       Date:  2006       Impact factor: 3.105

Review 3.  Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.

Authors:  Michele M Castro; Arulmozhi D Kandasamy; Nermeen Youssef; Richard Schulz
Journal:  Pharmacol Res       Date:  2011-05-31       Impact factor: 7.658

4.  The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction.

Authors:  Samad Ghaffari; Babak Kazemi; Mehdi Toluey; Nariman Sepehrvand
Journal:  Cardiovasc Ther       Date:  2013-08       Impact factor: 3.023

Review 5.  Cocoa and cardiovascular health.

Authors:  Roberto Corti; Andreas J Flammer; Norman K Hollenberg; Thomas F Lüscher
Journal:  Circulation       Date:  2009-03-17       Impact factor: 29.690

6.  Chocolate consumption and mortality following a first acute myocardial infarction: the Stockholm Heart Epidemiology Program.

Authors:  I Janszky; K J Mukamal; R Ljung; S Ahnve; A Ahlbom; J Hallqvist
Journal:  J Intern Med       Date:  2009-09       Impact factor: 8.989

Review 7.  Cyclosporine: mechanisms of action and toxicity.

Authors:  R M Graham
Journal:  Cleve Clin J Med       Date:  1994 Jul-Aug       Impact factor: 2.321

Review 8.  Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties.

Authors:  Giuseppe Galati; Peter J O'Brien
Journal:  Free Radic Biol Med       Date:  2004-08-01       Impact factor: 7.376

9.  Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO.

Authors:  Tiziano M Scarabelli; Anastasis Stephanou; Evasio Pasini; Gianluca Gitti; Paul Townsend; Kevin Lawrence; Carol Chen-Scarabelli; Louis Saravolatz; David Latchman; Richard Knight; Julius Gardin
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

10.  Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling.

Authors:  Francisco J Villarreal; Michael Griffin; Jeffrey Omens; Wolfgang Dillmann; Judy Nguyen; James Covell
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

View more
  5 in total

1.  κ-Opioid receptors are involved in enhanced cardioprotection by combined fentanyl and limb remote ischemic postconditioning.

Authors:  Ya-Chao Xu; Rui-Ping Li; Fu-Shan Xue; Xin-Long Cui; Shi-Yu Wang; Gao-Pu Liu; Gui-Zhen Yang; Chao Sun; Xu Liao
Journal:  J Anesth       Date:  2015-03-26       Impact factor: 2.078

2.  Cardiovascular Benefits of Dark Chocolate?

Authors:  Erin Higginbotham; Pam R Taub
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

3.  Catechin protects rat cardiomyocytes from hypoxia-induced injury by regulating microRNA-92a.

Authors:  Jian-Fei Fang; Jin-Hua Dai; Min Ni; Zhen-Yu Cai; Yu-Feng Liao
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

4.  Anticancer potential of (-)-epicatechin in a triple-negative mammary gland model.

Authors:  Georgina Almaguer; Pilar Ortiz-Vilchis; Paola Cordero; Rocío Martinez-Vega; Javier Perez-Durán; Eduardo Meaney; Francisco Villarreal; Guillermo Ceballos; Nayelli Nájera
Journal:  J Pharm Pharmacol       Date:  2021-12-07       Impact factor: 4.810

5.  Effect of minocycline on the left ventricular function following ST-elevation myocardial infarction treated by primary percutaneous coronary intervention.

Authors:  Alireza Nasiri; Akbar Shafiee; Ali Hosseinsabet; Azita Hajhosein Talasaz; Arash Jalali; Mojtaba Salarifar
Journal:  Trials       Date:  2022-02-04       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.